Following our findings on the anti-human immunodeficiency virus (HIV) activity of acyclovir (ACV) phosphate prodrugs, we herein report the ProTide approach applied to a series of acyclic nucleosides aimed at the identification of novel and selective antiviral, in particular anti-HIV agents. Acyclic nucleoside analogues used in this study were identified through a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate kinase, and human DNA polymerase γ. A total of 39 new phosphate prodrugs were synthesized and evaluated against HIV-1 (in vitro and ex vivo human tonsillar tissue system) and human herpes viruses. Several ProTide compounds showed substantial potency against HIV-1 at low micromolar range while the parent nucleosides were not effective. Also, pronounced inhibition of herpesvirus replication was observed. A carboxypeptidase-mediated hydrolysis study was performed for a selection of compounds to assess the formation of putative metabolites and support the biological activity observed.
Following our findings on the anti-human immunodeficiency virus (n class="Species">HIV) activity of acyclovir (ACV) phosphate prodrugs, we herein report the ProTide approach applied to a series of acyclic nucleosides aimed at the identification of novel and selective antiviral, in particular anti-HIV agents. Acyclic nucleoside analogues used in this study were identified through a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate kinase, and human DNA polymerase γ. A total of 39 new phosphate prodrugs were synthesized and evaluated against HIV-1 (in vitro and ex vivo human tonsillar tissue system) and human herpes viruses. Several ProTide compounds showed substantial potency against HIV-1 at low micromolar range while the parent nucleosides were not effective. Also, pronounced inhibition of herpesvirus replication was observed. A carboxypeptidase-mediated hydrolysis study was performed for a selection of compounds to assess the formation of putative metabolites and support the biological activity observed.
Authors: Christophe Vanpouille; Andrea Lisco; Jean-Charles Grivel; Leda C Bassit; Robert C Kauffman; Jorge Sanchez; Raymond F Schinazi; Michael M Lederman; Benigno Rodriguez; Leonid Margolis Journal: Clin Infect Dis Date: 2015-03-03 Impact factor: 9.079
Authors: W B Parker; E L White; S C Shaddix; L J Ross; R W Buckheit; J M Germany; J A Secrist; R Vince; W M Shannon Journal: J Biol Chem Date: 1991-01-25 Impact factor: 5.157
Authors: Christopher McGuigan; Karolina Madela; Mohamed Aljarah; Arnaud Gilles; Andrea Brancale; Nicola Zonta; Stanley Chamberlain; John Vernachio; Jeff Hutchins; Andrea Hall; Brenda Ames; Elena Gorovits; Babita Ganguly; Alexander Kolykhalov; Jin Wang; Jerry Muhammad; Joseph M Patti; Geoffrey Henson Journal: Bioorg Med Chem Lett Date: 2010-06-20 Impact factor: 2.823
Authors: Christophe Vanpouille; Andrea Lisco; Marco Derudas; Elisa Saba; Jean-Charles Grivel; Beda Brichacek; Francesca Scrimieri; Raymond Schinazi; Dominique Schols; Christopher McGuigan; Jan Balzarini; Leonid Margolis Journal: J Infect Dis Date: 2010-02-15 Impact factor: 5.226
Authors: Steve Tuske; Stefan G Sarafianos; Arthur D Clark; Jianping Ding; Lisa K Naeger; Kirsten L White; Michael D Miller; Craig S Gibbs; Paul L Boyer; Patrick Clark; Gang Wang; Barbara L Gaffney; Roger A Jones; Donald M Jerina; Stephen H Hughes; Eddy Arnold Journal: Nat Struct Mol Biol Date: 2004-04-25 Impact factor: 15.369
Authors: Christopher McGuigan; Marco Derudas; Joachim J Bugert; Graciela Andrei; Robert Snoeck; Jan Balzarini Journal: Bioorg Med Chem Lett Date: 2008-06-24 Impact factor: 2.823